Theriva Biologics Files 8-K on Financials
Ticker: TOVX · Form: 8-K · Filed: May 7, 2024 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | May 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, company-update
TL;DR
Theriva Biologics dropped an 8-K detailing their financial condition and results of operations.
AI Summary
On May 7, 2024, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. Theriva Biologics, incorporated in Nevada, is involved in the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing provides investors with crucial updates on Theriva Biologics' financial health and operational performance, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former company name
- ADEONA PHARMACEUTICALS, INC. (company) — Former company name
- PIPEX PHARMACEUTICALS, INC. (company) — Former company name
- May 7, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Theriva Biologics, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 7, 2024.
What is Theriva Biologics, Inc.'s state of incorporation?
Theriva Biologics, Inc. is incorporated in Nevada.
What was Theriva Biologics, Inc. formerly known as?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., and PIPEX PHARMACEUTICALS, INC.
What is Theriva Biologics, Inc.'s business address?
Theriva Biologics, Inc.'s business address is 9605 Medical Center Drive, Suite 270, Rockville, MD 20850.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-05-07 07:05:32
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2413496d1_8k.htm (8-K) — 26KB
- tm2413496d1_ex99-1.htm (EX-99.1) — 78KB
- tm2413496d1_ex99-1img01.jpg (GRAPHIC) — 12KB
- 0001104659-24-057689.txt ( ) — 303KB
- syn-20240507.xsd (EX-101.SCH) — 3KB
- syn-20240507_lab.xml (EX-101.LAB) — 33KB
- syn-20240507_pre.xml (EX-101.PRE) — 22KB
- tm2413496d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the "Registrant") issued a press release that included financial information for its quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated May 7, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 7, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer